
Guardant Health, Inc. (NASDAQ:GH) reported better-than-expected second-quarter financial results and raised its FY25 sales guidance above estimates on Wednesday.
Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.